[{"address1": "545 Concord Avenue", "address2": "Suite 210", "city": "Cambridge", "state": "MA", "zip": "02138", "country": "United States", "phone": "857 702 9600", "website": "https://www.neurobopharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Mr. Hyung-Heon  Kim", "age": 48, "title": "CEO, President, Principal Executive & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 625158, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marshall H. Woodworth", "age": 65, "title": "CFO, Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 154500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mi-Kyung  Kim", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Homolka", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.36, "open": 3.395, "dayLow": 3.3, "dayHigh": 3.52, "regularMarketPreviousClose": 3.36, "regularMarketOpen": 3.395, "regularMarketDayLow": 3.3, "regularMarketDayHigh": 3.52, "beta": -0.292, "forwardPE": -1.9748824, "volume": 14622, "regularMarketVolume": 14622, "averageVolume": 51293, "averageVolume10days": 22110, "averageDailyVolume10Day": 22110, "bid": 2.54, "ask": 4.22, "bidSize": 200, "askSize": 200, "marketCap": 28492734, "fiftyTwoWeekLow": 2.9, "fiftyTwoWeekHigh": 6.75, "fiftyDayAverage": 4.10668, "twoHundredDayAverage": 4.07067, "currency": "USD", "enterpriseValue": 632490, "floatShares": 2064467, "sharesOutstanding": 8486800, "sharesShort": 43631, "sharesShortPriorMonth": 52666, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0052, "heldPercentInsiders": 0.66233003, "heldPercentInstitutions": 0.12252, "shortRatio": 1.42, "shortPercentOfFloat": 0.014199999, "bookValue": 2.304, "priceToBook": 1.4571615, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -25899000, "trailingEps": -4.99, "forwardEps": -1.7, "lastSplitFactor": "1:25", "lastSplitDate": 1577750400, "enterpriseToEbitda": -0.024, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NRBO", "underlyingSymbol": "NRBO", "shortName": "NeuroBo Pharmaceuticals, Inc.", "longName": "NeuroBo Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1470403800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "df3dac6a-eed3-3175-b85d-a432fd732c3e", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.3573, "targetHighPrice": 48.0, "targetLowPrice": 10.0, "targetMeanPrice": 26.67, "targetMedianPrice": 22.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 28045000, "totalCashPerShare": 3.315, "ebitda": -26510000, "totalDebt": 170000, "quickRatio": 2.888, "currentRatio": 2.937, "debtToEquity": 0.897, "returnOnAssets": -0.57235, "returnOnEquity": -1.17355, "freeCashflow": -10436125, "operatingCashflow": -19900000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]